RPG Life Sciences Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹180Cr
- +4% YoY
- −1.1% QoQ
- Net profit
- ₹22Cr
- −37.1% YoY
- −40.5% QoQ
- Margin
- 22%
- −6 pp YoY
- +1 pp QoQ
Guidance rank: #80 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on RPG Life Sciences Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Revenue from Operations for Q3 FY26 was Rs. 180.0 crore, up from Rs. 172.7 crore in Q3 FY25 (+4.2% YoY). Q3 FY26 Financials vs Q3 FY25 (Page 14):.
From RPG Life Sciences Ltd's Q3 FY26 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Revenue from Operations for Q3 FY26 was Rs. 180.0 crore, up from Rs. 172.7 crore in Q3 FY25 (+4.2% YoY). (Page 14)
- EBITDA for Q3 FY26 was Rs. 43.2 crore, down from Rs. 52.5 crore in Q3 FY25 (-17.7% YoY). (Page 14)
- PBT for Q3 FY26 was Rs. 37.5 crore, down from Rs. 46.9 crore in Q3 FY25 (-20.0% YoY). (Page 14)
- PAT for Q3 FY26 was Rs. 27.9 crore, down from Rs. 34.8 crore in Q3 FY25 (-19.8% YoY). (Page 14)
- Domestic Formulations contributed 71% to total sales in Q3 FY26, International Formulations 18%, APIs 11%. (Page 16)
2 more points from RPG Life Sciences Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what RPG Life Sciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Since FY22, Rs. 140 crores capex infused for building a modern plant with approvals from EU, TGA, PMDA, and others. (Page 27)
- Modernization and capacity expansion underway for Formulations Units 1 and 2 at Ankleshwar. (Page 24)
- MF2 (Dedicated immunosuppressant facility), MF3, and MF4 multipurpose units are all undergoing modernization and capacity expansion; approvals include WHO GMP, TGA (Australia), PMDA (Japan), etc. (Page 24)
- State-of-the-art manufacturing capacity operating EU/TGA-approved plant with enhanced capacity for quality and compliance. (Page 22)
- Business transformation includes multiple infrastructure modernization and capacity expansion projects targeted at improving quality and manufacturing productivity. (Page 10, 9)
2 more points from RPG Life Sciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what RPG Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what RPG Life Sciences Ltd said on order book & pipeline — free account, 30 seconds.
RPG Life Sciences Ltd — Quarterly revenue & net profit
RPG Life Sciences Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 180 | 173 | +4% | 182 | -1.1% |
| Operating profit (EBITDA) | 40 | 49 | -18.4% | 39 | +2.6% |
| Operating margin | 22% | 28% | -6 pp | 21% | +1 pp |
| Profit before tax | 29 | 47 | -38.3% | 49 | -40.8% |
| Net profit (PAT) | 22 | 35 | -37.1% | 37 | -40.5% |
| EPS (₹) | 13.38 | 21.12 | -36.6% | 22.28 | -39.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹212 Cr, net profit ₹28 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What RPG Life Sciences's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q2 FY25 earnings call analysis →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
RPG Life Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were RPG Life Sciences Ltd Q3 FY26 results?
Revenue from Operations for Q3 FY26 was Rs. 180.0 crore, up from Rs. 172.7 crore in Q3 FY25 (+4.2% YoY). Q3 FY26 Financials vs Q3 FY25 (Page 14):.
What is RPG Life Sciences Ltd share price analysis?
RPG Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 39.7 with a market cap of ₹4,635 Cr. Investors should review the full earnings analysis for detailed insights.
Is RPG Life Sciences Ltd planning capital expenditure?
Since FY22, Rs. 140 crores capex infused for building a modern plant with approvals from EU, TGA, PMDA, and others.
Keep RPG Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
